230 results about "Methicillin resistant Staphylococcus" patented technology

The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.

Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant Staphylococcus aureus (MRSA). Disclosed are methods and compositions based on DNA sequences for the specific detection of MREJ sequences designated types xi, xii, xiii, xiv, xv, xvi, xvii, xviii, xix, and xx for diagnostic purposes and/or epidemiological typing.

Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and also antimicrobial agents comprising these compounds, and pharmaceutical compositions comprising these compounds as an active component.

The invention provides a bacterial strain for preparing a phenyllactic acid and a method for preparing phenyllactic acid through bacterial strain fermentation, belonging to the food biotechnology. The invention discloses a pediococcus lactobacillus for preparing phenyllactic acid and particularly relates to Pediococcus pentosaceus SK25 capable of preparing phenyllactic acid, which is preserved inthe China center for type culture collection with a collection number of CCTCC NO: M2011360. According to the method provided by the invention, the pediococcus is used as a starting bacterial strain.In an MRS (Methicillin Resistant Staphylococcus) culture medium fermentation liquor, the content of phenyllactic acid reaches 0.8 mmol/L. At present, the reported maximum yield of wild bacterial strains in the MRS culture medium fermentation liquor is only 0.57 mmol/L. When phenylalanine or phenylpyruvic acid is added to the MRS culture medium, the yield of phenyllactic acid is improved. If the phenylpyruvic acid is added in the MRS culture medium, the improvement of the yield of the phenyllactic acid is obvious, and the optimal addition quantity is determined to be 5-6 mmol/L. The product obtained by the invention is safe and reliable, can be used as a medicinal intermediate and a food additive, and has a very strong antibacterial and antiseptic function.

The invention relates to a method for producing sourdough bread by utilizing lactobacillus plantarum fermented dough. The method comprises the following steps: (1) activating and cultivating lactobacillus plantarum powder on an MRS (Methicillin Resistant Staphylococcus) culture medium, applying the activated bacterium liquid to the fresh MRS culture medium, and culturing again, thereby obtaining the activated bacterium liquid; (2) centrifuging the activated bacterium liquid to obtain a solid, washing the solid with sterile physiological saline water, adding water and high-gluten wheat flour, and culturing in a constant-temperature culturing box, thereby obtaining ripe lactobacillus plantarum fermented dough; (3) taking the high-gluten wheat flour (namely, activated dry yeast), salt and sugar, adding water and the ripe lactobacillus plantarum fermented dough, stirring and then adding shortening, and continuing to stir; (4) taking out the dough, standing by, cutting and forming; and (5) after lastly fermenting the dough, baking the dough, thereby obtaining the sourdough bread. According to the method provided by the invention, the nutritional value of the bread is increased, the sourdough bread can be fermented so as to generate antibacterial matter, the bread is prevented from going bad, and the shelf life of the bread is prolonged.

The invention discloses water, ethanol and ethanol aqueous extracts of traditional Chinese medicine pithecellobium clypearia and application of corresponding petroleum ether, ethyl acetate, normal butanol and a water extractants in preparation of medicines for treating methicillin-resistant staphylococcus aureus (MRSA) and antibiotics anti-MRSA sensitization medicines. Meanwhile, the invention further discloses a preparation method of the extracts or extractants. Experimental results show that water, 10% ethanol, 30% ethanol, 60% ethanol, 95% ethanol extracts of pithecellobium clypearia and corresponding ethyl acetate, normal butanol and water extractants have stronger anti-MRSA effect, wherein the activity of the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia is the strongest, and the ethyl acetate extracting part of the 60% ethanol extract of pithecellobium clypearia has sensitization effect on erythrocin, ceftriaxone sodium, levofloxacin for treating MRSA.

The invention discloses an antibacterial peptide SE37, and belongs to the biotechnical field. The amino acid sequence of the antibacterial peptide SE37 is Ser-Glu-Thr-Arg-Pro-Val-Leu-Asn-Arg-Leu-Phe-Asp-Lys-Ile-Arg-Gln-Val-Ile-Arg-Lys-Phe-Glu-Lys-Gly-Ile-Lys-Glu-Lys-Ser-Lys-Arg-Phe-Phe-Asp-Gly-Leu-Leu. Experiments prove that the antibacterial peptide has an obvious inhibition effect on Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and four methicillin-resistant Staphylococcus aureuses, has the advantages of very low hemolysis activity, good stability, strong antibacterial activity and high-efficiency and wide-spectrum antibacterial effect, and can be used as an antibiotic substitute.

The invention discloses a triple real-time fluorescent PCR (polymerase chain reaction) detection primer, a detection probe, a detection kit and a detection method for methicillin-resistant staphylococcus aureus. The detection primer and the detection probe are designed according to nuc, mecA and femA gene sequences respectively; through the detection primer and the detection probe, triple real-time fluorescent PCR detection is performed on a sample according to the detection method; in a primary amplification reaction, the detection on the specificity of the methicillin-resistant staphylococcus aureus in the sample to be detected is completed so as to simply, conveniently, rapidly and accurately judge whether the sample to be detected contains the methicillin-resistant staphylococcus aureus. When the triple real-time fluorescent PCR detection is performed on the sample according to the detection method, the detection is rapid and a process from sample preparation to detection result obtainment can be completed within 8-10 hours; interferences from false positiveness, cross contamination and the like can be avoided; the detection result is reliable, the detection sensitivity is high, and the detection specificity is high; and a beneficial tool is provided for epidemiological survey through the methicillin-resistant staphylococcus aureus.

The invention relates to application of the combination of any two or three combined catechin substances with antibiotics in preparing antibacterial drugs. The combination of the combined catechin substances with the antibiotics is applied to the field of resisting MRSA (Methicillin-Resistant Staphylococcus Sureus) and can provide the antibacterial and sensitivity increasing effects of drugs. The invention not only broadens the application of the catechin substances and the application scheme thereof, but also can reduce the phenomena of drug resistance generated by the MRSA due to the abuse of the traditional antibacterial drugs.

The invention relates to a double-chain small molecule interference nucleic acid for inhibiting and killing various drug tolerance bacteria using methicillin-resistant staphylococcus aurous as represents. The siNA of the invention is a double-chain molecule with 19 base pairs. A sense strand and a antisense strand respectively have two overhanging bases dT at 5' terminals, the GC content is 40-55; the aimed target sequence is selected from the genes relative with the vital movements of copy, transcription and translation in the staphylococcus aurous genome and an mecA gene correlative with the drug tolerance; said target sequence is preserved in 900f staphylococcus aurous; said target sequence is in a conservative sequence area in more than 900f staphylococcus aurous with distinct source with all the gene sequences in the human genome; the target sequence of the said siNA double-chain molecule is selected from SEQ ID NO. 1-325, the sense strand is a corresponding DNA or RNA sequence with the target sequence and the antisense strand is a corresponding RNA or DNA with the sense strand according to the complementary base law.

The invention discloses an application of a macrolide compound or a salt thereof and a pharmaceutical composition containing the macrolide compound or the salt, and provides a pharmaceutical composition. The pharmaceutical composition comprises one or more of a macrolide compound as shown in a formula 1 in the specification, a macrolide compound as shown in a formula 1' in the specification and pharmaceutically acceptable salts thereof, and beta-lactam antibiotics. One or more of the macrolide compound as shown in the formula 1, the macrolide compound as shown in the formula 1' and pharmaceutically acceptable salts thereof disclosed by the invention has/have the effects of improving the effects of beta-lactam antibiotics and inhibiting methicillin-resistant staphylococcus aureus (MRSA); the macrolide compound is a novel synergist, is good in in-vitro synergism, is capable of relieving the drug resistance of the methicillin-resistant staphylococcus aureus (MRSA) on beta-lactam antibiotics, and is a medicine with good market development prospect.

The invention discloses a virus-killing mask and a preparation method of a mask filter layer. The middle layer of the mask body is at least one layer of melt-blown non-woven fabric made of a virus-killing filter layer; the virus-killing filter layer is made of a polypropylene composite material, is a virus-killing polypropylene composite material, and is prepared from the following components in percentage by weight: 95-99% of polypropylene and the balance of a nano silver-copper alloy material; the nano-silver copper alloy material is formed by mixing nano-silver copper alloy particles with the particle size of 15 nm-50 nm, the copper metal atom form of the outer surface of the alloy material is copper oxide, and the nano-silver copper alloy material comprises, by weight, 40%-80% of silver and the balance copper. Through detection, the antibacterial rate of the virus-killing mask on escherichia coli and staphylococcus aureus representing conventional strains and methicillin-resistantstaphylococcus aureus representing super bacteria reaches 99% or above.

The invention provides a novel cyclic hexapeptide antibacterial compound yanglingmycins, belonging to the technical field of medicaments. The compound in the invention has a structural formula shown in the specification. The amino acid composition of the cyclic hexapeptide antibacterial compound comprises valine and other unconventional amino acids, such as 2-methylamino propionic acid, piperazin-3-carboxylic acid and 6-chloro-3alpha-hydroxy-1, 2, 3, 3alpha, 8, 8alpha-hexyhydro [2, 3-pyrrolo] indol-2-carboxylic acid, wherein each amino acid is in an L configuration or a D configuration. The compound in the invention can strongly inhibit many kinds of gram positive bacteria such as bacillus cereus, bacillus subtilis, staphylococcus aureus and methicillin resistant staphylococcus aureus.

The invention discloses macrolactone compounds or salts of the macrolactone compounds, as well as a synthesis method, a pharmaceutical composition and application of the macrolactone compounds or salts. The invention provides a macrolactone compound 1, a macrolactone compound 1' or salts of the macrolactone compound 1 and the macrolactone compound 1', a pharmaceutical composition containing the macrolactone compound 1, the macrolactone compound 1' or the salts of the macrolactone compound 1 and the macrolactone compound 1' and application of the pharmaceutical composition in preparing a drug for inhibiting methicillin-resistant staphylococcus aureus. When one or more of the macrolactone compound 1, the macrolactone compound 1', the salt of the macrolactone compound 1 and the salt of the macrolactone compound 1' are jointly used in combination with beta-lactam antibiotics, the inhibiting effect of the beta-lactam antibiotics on the methicillin-resistant staphylococcus aureus can be obviously increased. The macrolactone compounds and the salts thereof are novel synergists having good in-vitro synergistic effect, can alleviate the drug resistance of the methicillin-resistant staphylococcus aureus to the beta-lactam antibiotic and are drug having good market development prospects.

The invention discloses a preparation method of bacterial cellulose with the antimicrobial property. Gluconacetobacter GD-BC-1 is taken for fermentation cultivation, to obtain the bacterial cellulose contained fermentation liquor, antimicrobial peptide produced bacteria are added into the fermentation liquor, the antimicrobial peptide produced bacteria are embedded in the bacterial cellulose to continue to ferment, the cellulose group contained bacteria liquid is obtained, a cellulose group is taken out to be placed into an MRS (Methicillin Resistant Staphylococcus) culture medium to be cultured, the cellulose group is taken out to be rinsed through water, and the bacterial cellulose with the antimicrobial property is obtained. According to the preparation method of the bacterial cellulose with the antimicrobial property, the antimicrobial peptide produced bacteria are wrapped in the bacterial cellulose synthesis process by a mixed multi-fermentation method; the fermentation culture medium is transformed to enable antimicrobial peptide to be synthesized through the antimicrobial peptide produced bacteria to be hung on the bacterial cellulose and accordingly the bacterial cellulose with the antimicrobial property is prepared; the problem of the toxic effect on the bacterial cellulose produced bacteria due to direct adding of an antibacterial agent is solved; the complicated preparation process of the traditional antimicrobial bacterial cellulose is simplified.

The invention relates to application of patchouli alcohol in preparing medicines treating bacteria infectious diseases and further provides a medicine composition treating the bacteria infectious diseases. The patchouli alcohol has excellent inhibitory activity to pathogenic bacteria or conditional pathogenic bacteria and can effectively treat the bacteria infectious diseases, meanwhile, the patchouli alcohol can also effectively resist methicillin-resistant staphylococcus epidermidi drug-resistance bacteria, the pharmacodynamics activity of the patchouli alcohol equals to vancomycin, and therefore probability is provided for slowing or avoiding occurring of the drug-resistance bacteria.

The invention discloses application of dihydroquercetin and glucoside compounds to preparing a medicine for resisting drug-fast bacteria. With the invention, the dihydroquercetin and glucoside compounds can be extracted from decogenus plants, such as hypericum japonicum Thunb, and the activity of the dihydroquercetin and glucoside compounds for resisting the drug-fast bacteria can be proved; proved by a pharmacological experiment, the dihydroquercetin and glucoside compounds not only have remarkable direct inhibition function on common-clinically meticillin-resistant staphylococcus aureus (MRSA), but also can enhance the action of the traditional antibiotic for resisting the drug-fast bacteria. The dihydroquercetin and glucoside compounds can be further used as active components and used for preparing a medicine for treating the drug-fast bacteria infection; and preparation forms includes oral preparations, injections and/or external preparations which are prepared by combining with acceptable carriers.

The invention discloses Peptaibol antibacterial peptide compounds and a preparation method and application thereof. The four novel Peptaibol antibacterial peptide compounds are separated and obtained from acremonium persicinum SC0105 fermentation products, and it is shown through antibacterial tests that the antibacterial peptide compounds have a remarkable inhibition effect on staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). Peptaibol antibacterial peptide is a main metabolic product of a strain, the yield is high, and high research and development potential is achieved. The Peptaibol antibacterial peptide can serve as an antibiotic substitute and be applied to medicine for preparing antibacterial drugs and feed additives in the breeding industry.

The invention relates to a purification method in preparation of methicillin staphylococcus aureus-resistant recombinant di-subunit genetic engineering vaccine candidate antigen I12C, which comprises the following steps of: collecting prepared antigen; and carrying out high-pressure bacterium breaking and centrifuging, precipitating ammonium sulfate step by step to purify the prepared I12C antigen according to the sequential combination, i.e., the GST (glutathione s transferase) affinity chromatography technology, the PP (propene polymer) digestion technology, the buffer solution replacement technology, the Resource Q chromatography technology and the gel filtration chromatography technology. The purification method provided by the invention is simple and direct, easy to amplify, and good in repeatability, so that the obtained target protein is high in purity; the animal experiment proves that the purified antigen can effectively stimulate the organism to generate higher humoral immune response and have good immune protection function; and the purity of the antigen I12C purified by the method provided by the invention is more than or equal to 99%.

The invention discloses a reagent kit and method for quickly detecting staphylococcus MecA. The reagent kit comprises cell lysate, amplifying reaction liquid, colloidal gold detection liquid and an immunochromatography reagent strip. The reagent kit is characterized in that transcription products of MecA and 16S rRNA are obtained through NASBA amplification on a primer pair in the amplifying reaction liquid. The reagent kit for quickly detecting genes of the staphylococcus MecA is stable in detection result, high in accuracy rate, high in sensitivity, low in cost and short in time consumptionand suitable for clinical promotion. The detection method is suitable for clinically and quickly detecting methicillin resistant staphylococcus and screening staphylococcus at pharynx nasalis, is quick and accurate, is simple in equipment, is low in requirements for operators, and has potential in bedside detection and application in hospitals at different levels.

The invention provides a method for extracting methicillin-resistant staphylococcus aureus DNA (Deoxyribonucleic Acid). The method comprises the following steps of: preparing a lysis solution (pH 8.2) by the following components in final concentration: 20mM of Tris, 2mM of Na2-EDTA (Ethylene Diamine Tetraacetic Acid), 1.0% of Tritonx-100, 20mg/ml of lysozyme, 0.05g/ml-0.15g/ml of chelex100, 90mu g/ml-100mu g/ml of lysostaphin, 1.8mg/ml-2mg/ml of protease K and the balance of sterile water; getting and suspending 5-10 staphylococcus aureus bacterial colonies, which grow on the solid culture medium, in the 100mu l of the lysis solution, centrifuging for 30 minutes at 56 DEG C, 10 minutes at 100 DEG C and 10 minutes at the speed of 12000rpm; and getting and using the liquid supernatant for the PCR (Polymerase Chain Reaction).

The invention relates to a method of improving the freezing resistance of lactic acid bacteria sour dough leavening agent freeze-dried powder by using a composite preservative agent, and belongs to the technical field of food processing. The method comprises the steps: activating lactic acid bacteria powder on an MRS (Methicillin Resistant Staphylococcus) culture medium, spreading cultivation, then centrifuging an activated bacteria liquid, adding high gluten wheat flour, water, gamma-polyglutamic acid, mycose, glycerol and dried skim milk, uniformly mixing, and putting a mixture in a constant temperature cultivation box for cultivation to obtain a mature lactic acid bacteria fermentation sour dough leavening agent; then freeze-drying the lactic acid bacteria fermentation sour dough leavening agent by using a vacuum freeze drier, and crushing, thus obtaining the lactic acid bacteria sour dough leavening agent freeze-dried powder finished product; and storing the finished product at the temperature of below 4 DEG C in a sealing manner. The product has relatively good freezing resistance. After the product is stored for 30 days at the temperature of 40 DEG C, the lactic acid bacteria activity of the product is still above 80%. The lactic acid bacteria sour dough leavening agent freeze-dried powder can serve as a direct vat set sour sough leavening agent to be applied in baking food and is capable of improving the texture, flavor and nutritive peculiarity of food and simplifying the application of a lactic acid bacteria sour dough fermentation technology in baking food.